IVL

Across TCGA pan-cancer cohorts, IVL mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IVL data layer compared with 20 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IVL mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IVL expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where IVL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.277	0.657	.001	40	view →
HNSC	OS	Median	All	0.914	0.785	.006	14	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.792	.006	7	view →
LUAD	OS	Tertile	III,IV	0.931	0.404	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IVL–PDAC (OS)

Open the PDAC breakdown →